[1. Singbartl K, Kellum JA. AKI in the ICU: definition, epidemiology, risk stratification, and outcomes. Kidney Int 2012; 81(9): 819-25.10.1038/ki.2011.33921975865]Search in Google Scholar
[2. Ostermann M, Joannidis M. Acute Kidney Injury 2016: diagnosis and diagnostics workup. Crit Care 2016; 20(1): 299-312.10.1186/s13054-016-1478-z503764027670788]Search in Google Scholar
[3. Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA 2016; 315(8): 801-10.10.1001/jama.2016.0287496857426903338]Search in Google Scholar
[4. Angus DC, Van der Pol T. Severe Sepsis and Septic Shock. N Engl J Med 2013; 369(9): 840-51.10.1056/NEJMra120862323984731]Search in Google Scholar
[5. Martensson J, Bellomo R. Sepsis-Induced Acute Kidney Injury. Crit Care Clin 2015; 31(4): 649-660.10.1016/j.ccc.2015.06.00326410135]Search in Google Scholar
[6. Swaminathan S, Rosner MH, Okusa MD. Emerging Therapeutic Targets of Sepsis-Associated Acute Kidney Injury. Semin Nephrol 2015; 35(1): 38-54.10.1016/j.semnephrol.2015.01.005436932025795498]Search in Google Scholar
[7. Rizo-Topete L, Ronco C. Critical Care Nephrology: A Multidisciplinary Approach. Blood Purif 2017; 43: 53-6.10.1159/00045301827915328]Search in Google Scholar
[8. Petrović D, Mijailović Ž, Popovska B, Miloradović V, Đurđević P. Sepsis and cardiorenal syndrome: etiopatho-genesis, diagnosis and treatment. Ser J Exp Clin Res 2013; 14(4): 181-7.10.5937/sjecr14-4363]Search in Google Scholar
[9. Hamzagić N, Nikolić T, Popovska Jovičić B, Čanović P, Jaćović S, Petrović D. Acute kidney damage: definition, classification and optimal time of hemodialysis. Ser J Exp Clin Res 2017; DOI: 10.1515/sjecr-2017-0050.10.1515/sjecr-2017-0050]Search in Google Scholar
[10. Fissell WH. Antimicrobial Dosing in Acute Renal Replacement Therapy. Adv Chronic Kidney Dis 2013; 20(1): 85-93.10.1053/j.ackd.2012.10.004380724923265600]Search in Google Scholar
[11. Shaw AR, Mueller BA. Antibiotic Dosing in Continuous Renal Replacement Therapy. Adv Chronic Kidney Dis 2017; 24(4): 219-27.10.1053/j.ackd.2017.05.00428778361]Search in Google Scholar
[12. Udy AA, Roberts JA, Boots RJ, Paterson DL, Lipman J. Augmented Renal Clearance: Implications for Antibacterial Dosing in the Critically ill. Clin Pharmacokinet 2010; 49(1): 1-16.10.2165/11318140-000000000-0000020000886]Search in Google Scholar
[13. Udy AA, Roberts JA, Shorr AF, Boots RJ, Lipman J. Augmented renal clearance in septic and traumatized patients with normal plasma creatinine concentrations: identifying at-risk patients. Crit Care 2013; 17: R35.10.1186/cc12544405678323448570]Search in Google Scholar
[14. Hobbs AL, Shea KM, Roberts KM, Daley MJ. Implications of Augmented Renal Clearance on Drug Dosing Critically Ill Patients: A Focus on Antibiotics. Pharmacotherapy 2015; 35(11): 1063-75.10.1002/phar.165326598098]Search in Google Scholar
[15. Mahmoud SH, Shen C. Augmented Renal Clearance in Critical Illness: An Important Consideration in Drug Dosing. Pharmaceutics 2017; 9(3): 36-63.10.3390/pharmaceutics9030036]Search in Google Scholar
[16. KDIGO Clinical Practice Guideline for Acute Kidney Injury. AKI Dewfinition. Kidney Int Suppl 2012; 2(1): 19-36.10.1038/kisup.2011.32408959525018918]Search in Google Scholar
[17. Zarbock A, Gomez H, Kellum JA. Sepsis-induced AKI revisited: pathophysiology, prevention and future therapies. Curr Opin Crit Care 2014; 20(6): 588-95.10.1097/MCC.0000000000000153449565325320909]Search in Google Scholar
[18. Gomez H, Ince C, Backer DD, Pickkers P, Payen D, Hotchkiss J, Kellum JA. A Unified Theory of Sepsis-Induced Acute Kidney Injury: Inflammation, microcirculation dysfunction, bioenergetics and the tubular cell adaptation to injury. Shock 2014; 41(1): 3-11.10.1097/SHK.0000000000000052391894224346647]Search in Google Scholar
[19. Doi K. Role of kidney injury in sepsis. J Intensive Care 2016; 4: 17. DOI: 10.1186/s40560-016-0146-3.10.1186/s40560-016-0146-3480451727011788]Search in Google Scholar
[20. Kellum JA, Chawla LS. Cell-cycle arrest and acute kideny injury: the light and the dark side. Nephrol Dial Transplant 2016; 31(1): 16-22.10.1093/ndt/gfv130470304826044835]Search in Google Scholar
[21. Lameire N, Vanmassenhove, Van Biesen W, Vanholder R. The cell cycle biomarkers: promising research, but do not oversell them. Clin Kidney J 2016; 9(3): 353-8.10.1093/ckj/sfw033488692327274818]Search in Google Scholar
[22. Palevsky PM. Renal Replacement Therapy in Acute Kidney Injury. Adv Chronic Kidney Dis 2013; 20(1): 76-84.10.1053/j.ackd.2012.09.004353187723265599]Search in Google Scholar
[23. Heung M, Yessayan L. Renal Replacement Therapy in Acute Kidney Injury: Controversies and Consensus. Crit Care Clin 2017; 33(2): 365-78.10.1016/j.ccc.2016.12.00328284300]Search in Google Scholar
[24. Bagshaw SM, Cruz DN, Gibney RTN, Ronco C. A proposed algorithm for initiation of renal replacement therapy in adult critically ill patients. Crit Care 2009; 13(6): 317-2510.1186/cc8037281190619909493]Search in Google Scholar
[25. Wald R, Bagshaw SM. The Timing of Renal Replacement Therapy Initiation in Acute Kidney Injury. Semin Nephrol 2016; 36(1): 78-84.10.1016/j.semnephrol.2016.01.00927085738]Search in Google Scholar
[26. Shiao CC, Huang TM, Spapen HD, Honore PM, Wu VC. Optimal timing of renal replacement therapy initiation in acute kidney injury: the elephant felt by the blidmen? Crit Care 2017; 21: 146. DOI: 10.1186/s13054-017-1713-2.10.1186/s13054-017-1713-2547714728629397]Search in Google Scholar
[27. Bagshaw SM, Wald R. Strategies for the optimal timing to start renal replacement therapy in critically ill patients with acute kidney injury. Kidney Int 2017; 91(2): 1022-32.10.1016/j.kint.2016.09.053]Search in Google Scholar
[28. Murugan R, Hoste E, Mehta RL, Samoni S, Ding X, Rosner MH, Kellum JA, Ronco C on behalf of the Acute Disease Quality Initiative (ADOQI) Consensus Group. Precision Fluid Management in Continuous Renal Replacement Therapy. Blod Purif 2016; 42(3): 266-78.10.1159/00044852827562336]Search in Google Scholar
[29. Macedo E, Mehta RL. Continous Dialysis Therapies: Cor Curriculum 2016. Am J Kidney Dis 2016; 68(4): 645-57.10.1053/j.ajkd.2016.03.42727241853]Search in Google Scholar
[30. Rimmele T, Kellum JA. Clinical review: Blood purification for sepsis. Crit Care 2011; 15(1): 205. DOI: 10.1186/cc9411.10.1186/cc9411322204021371356]Search in Google Scholar
[31. Oda S, Aibiki M, Ikeda T, Imaizumi H, Endo S, Ochai R, Kotani J, Shime N, Nishida O, Noguchi T, Matsuda N, Hirasawa H and Sepsis Registry Committee of The Japanese Society of Intensive Care Medicine. The Japanese guidelines for the management of sepsis. J Intesive Care 2014; 2: 55. DOI: 10.1186/s40560-014-0055-2.10.1186/s40560-014-0055-2433627325705413]Search in Google Scholar
[32. Hattori N, Oda S. Cytokine-adsorbing hemofilter: old but new modality for septic acute kidney injury. Renal Replacement Therapy 2016; 2: 41. (DOI: 10.1186/s41100-016-0051-1.10.1186/s41100-016-0051-1]Search in Google Scholar
[33. Tanaka A, Inaguma D, Nakamura T, Watanabe T, Ito E, Kamegai N, et al. Effect of continuous hemodiafiltration using an AN69ST membrane in patients with sepsis. Renal Replacement Therapy 2017; 3: 12. (DOI: 10.1186/s41100-017-0093z).10.1186/s41100-017-0093-z]Search in Google Scholar
[34. Baldwin I, Fealy N. Clinical Nursing for the Application of Continuous Renal Replacement Therapy in the Intensive Care Unit. Semin Dial 2009; 22(2): 189-93.10.1111/j.1525-139X.2008.00547.x19426427]Search in Google Scholar
[35. Bagshaw SM, Chakravarthi MR, Ricci Z, Tolwani A, Neri M, De Rosa S, Kellum JA, Ronco C, on behalf of the ADQI Consensus Group. Precision Continuous Renal Replacement Therapy and Solute Control. Blood Purif 2016; 42(3): 238-47.10.1159/00044850727562079]Search in Google Scholar
[36. Nolin TD, Aronoff GR, Fissel WH, Jain L, Madabushi R, Reynolds K, et al. Pharmacokinetic Assessment in Patients Receiving Continuous RRT: Perspectives from the Kidney Health Initiative. Clin J Am Soc Nephrol 2015; 10(1): 159-64.10.2215/CJN.05630614428441625189923]Search in Google Scholar
[37. Böhler J, Donauer J, Keller F. Pharmacokinetic principles during continuous renal replacement therapy: Drugs and dosage. Kidne Int 1999; 56(Suppl 72): 24-8.10.1046/j.1523-1755.1999.07202.x]Search in Google Scholar
[38. Churchwell MD, Mueller BA. Drug Dosing During Continuous Renal Replacement Therapy. Semin Dial 2009; 22(2): 185-8.10.1111/j.1525-139X.2008.00541.x19426426]Search in Google Scholar
[39. Lewis SJ, Mueller BA. Antibiotics Dosing in Patients With Acute Kidney Injury: “Enough But Not Too Much”. J Intensive Care Med 2016; 31(3): 164-76.10.1177/088506661455549025326429]Search in Google Scholar
[40. Choi G, Gomersall CD, Tian Q, Joynt GM, Li AMMY, Lipman J. Principles of Antibacterial Dosing in Continuous Renal Replacement Therapy. Blood Purif 2010; 30(3): 195-212.10.1159/00032148820924175]Search in Google Scholar
[41. Bugge JF. Pharmacokinetics and drug dosing adjustment during continuous venovenous hemofiltration or hemodiafiltration in critically patients. Acta Anaesthesiol Scand 2001; 45(8): 929-34.10.1034/j.1399-6576.2001.450802.x11576041]Search in Google Scholar
[42. Blot SI, Pea F, Lipman J. The effect of pathophysiology on pharmacokinetics in the critically ill patient-Concepts appraised by the example of antimicrobial agents. Adv Drug Del Rev 2014; 77(1): 3-11.10.1016/j.addr.2014.07.00625038549]Search in Google Scholar
[43. Honore PM, Jacobs R, De Waele E, Spapen HD. Applyng pharmacokinetic/pharmacodynamic principles for optimizing antimicrobial therapy during continuous renal replacement therapy. Anaestesiol Intensive Therapy 2017; 49(5): 412-8.10.5603/AIT.a2017.007129171000]Search in Google Scholar
[44. Taccone FS, De Backer D, Laterre PF, Spapen H, Dugernier T, Delattre I, et al. Pharmacokinetics of loading dose of amikacin in septic patients undergoing continuous renal replacement therapy. Int J Antimicrob Agents 2011; 37(6): 531-5.10.1016/j.ijantimicag.2011.01.02621489756]Search in Google Scholar
[45. Roger C, Wallis SC, Muller L, Saissi G, Lipman J, Lefrant JY, Roberts JA. Influence of Renal Replacement Modalities on Amikacin Population Pharmacokinetics in Critically Ill Patients on Continuous Renal Replacement Therapy. Antimicrob Agents Chemother 2016; 60(8): 4901-9.10.1128/AAC.00828-16495815427270279]Search in Google Scholar
[46. De Winter S, Wauters J, Meersseman W, Verhaegen J, Wijngaerden EV, Peetermans W, et al. Higher versus standard amikacin single dose in emergency departemnt patients with severe sepsis and septic shock: a randomised controlled trial. Int J Antimicrob Agents 2018; 51(4): 562-70.10.1016/j.ijantimicag.2017.11.00929180278]Search in Google Scholar
[47. D′Avolio A, Pensi D, Baietto L, Pacini G, Di Perri G, De Rosa FG. Daptomycin Pharmacokinetics and Pharmaco-dynamics in Septic and Critically Ill Patients. Drugs 2016; 76(12): 1161-74.10.1007/s40265-016-0610-327412121]Search in Google Scholar
[48. Soraluce A, Asin-Prieto E, Rodriquet-Gascon A, Barrasa H, Mayner J, Carcelero E, et al. Population pharmacokinetics of daptomycin in critically ill patients. Int J Anti-microb Agents 2018; 52(2): 158-65.10.1016/j.ijantimicag.2018.03.00829572042]Search in Google Scholar
[49. Villa G, Di Maggio P, De Gaudio AR, Novelli A, Antoniotti R, Ficcadori E, Adembri C. Effects of continuous renal replacement therapy on linezolid pharmacokinetic/phamacodynamics: a systematic review. Crit Care 2016; 20(1): 374.10.1186/s13054-016-1551-7511621827863531]Search in Google Scholar
[50. Taubert M, Zander J, Frechen S, Scharf C, Frey L, Vogeser M, Fuhr U, Zoller M. Optimization of linezolid therapy in the critically ill: the effect of adjusted infusion regimens. J Antimicrob Chemother 2017; 72(8): 2304-10.10.1093/jac/dkx14928541510]Search in Google Scholar
[51. Beumier M, Roberts JA, Kabtouri H, Hites M, Cotton F, Wolf F, et al. A new regimen for continuous infusion of vancomycin during continuous renal replacement therapy. J Antimicrob Chemother 2013; 68(12): 2859-65.10.1093/jac/dkt26123800905]Search in Google Scholar
[52. Roberts JA, Taccone FS, Udy AA, Vincent JL, Jacobs F, Lipman J. Vancomycin Dosing in Critically Ill Patients: Robust Methods for Improved Continuous-Infusion Regimens. Antimicrob Agents Chemother 2011; 55(6): 2704-9.10.1128/AAC.01708-10310140721402850]Search in Google Scholar
[53. Vandecasteele SJ, Vriese ASD, Tacconelli E. The pharmacokinetics and pharmacodynamics of vancomycin in clinical practice: evidence and uncerainies. J Antimicrob Chemother 2013; 68(4): 743-48.10.1093/jac/dks49523249839]Search in Google Scholar
[54. Filippone EJ, Kraft WK, Farber JL. The Nephrotoxicity of Vancomycin. Clin Pharm Ther 2017; 102(3): 459-469.10.1002/cpt.726557976028474732]Search in Google Scholar
[55. Beumier M, Casu GS, Hites M, Seyler L, Cotton F, Vincent JL, et al. β-lactam antibiotic concentrations during continuous rena replacement therapy. Crit Care 2014; 18: R105.10.1186/cc13886407512224886826]Search in Google Scholar
[56. Mariat C, Venet C, Jehl F, Mwewa S, Lazarevic V, Diconne E, et al. Continuous infusion of ceftazidime in critically ill patients undergoing continuous venovenous haemodiafiltration: pharmacokinetic evaluation and dose recommendation. Crit Care 2016; 10(1): R26.10.1186/cc3993155079616507147]Search in Google Scholar
[57. Isla A, Gascon AR, Maynar J, Pedraz JL. Cefepime and continuous renal replacement therapy (CRRT): In vitro pemeability of two CRRT membranes and pharmacokinetics in four critically patients. Clin Ther 2005; 27(5): 599-608.10.1016/j.clinthera.2005.05.00415978309]Search in Google Scholar
[58. Malone RS, Fish DN, Abraham E, Teitelbaum I. Pharmacokinetics of Cefepime during Continuous Renal Replacement Therapy in Critically Ill Patients. Antimicrob Agents Chemotherapy 2001; 45(11): 3148-55.10.1128/AAC.45.11.3148-3155.20019079611600370]Search in Google Scholar
[59. Roger C, Cotta MO, Muller L, Wallis SC, Lipman J, Lefrant JY, Roberts JA. Impact of renal replacement modalities on the clearance of pipracillin-tazobactam administered via continuous infusion in critically ill patients. Int J Antimicrob Agents 2017; 50(2): 227-31.10.1016/j.ijantimicag.2017.03.01828689876]Search in Google Scholar
[60. Asin-Prieto E, Rodriguez-Gascon A, Troconiz I, Soraluce A, Maynar J, Sanchez-Izquierdo JA, et al.Population pharmacokinetics of piperacillin and tazobactam in critically ill patients undergoing continuous renal replacement therapy: application to pharmacokinetic/pharmaco-dynamic analysis. J Antimicrob Chemother 2014; 69(1): 180-9.10.1093/jac/dkt30423908259]Search in Google Scholar
[61. Menna P, Salvatorelli E, Mattei A, Cappiello D, Minotti G, Carassiti M. Modified Colistin Regimen for Critically ill Patients with Acute Renal Impairment and Continuous Renal Replacement Therapy. Chemotherapy 2018; 63(1): 35-8.10.1159/00048497429334366]Search in Google Scholar
[62. Markou N, Fousteri M, Markantonis SL, Zidianakis B, Hroni D, Boutzouka E, Baltopoulos G. Colistin pharmacokinetics in intensive care units patients on continuous venovenous haemodiafiltration: an observational study. J Antimicrob Chemother 2012; 67(10): 2459-62.10.1093/jac/dks25722790220]Search in Google Scholar
[63. Fiaccadori E, Antonucci E, Morabito S, dAvolio A, Maggiore U, Regolisti G. Colistin Use in Patients With Reduced Kidney Function. Am J Kidney Dis 2016; 68(2): 196-306.10.1053/j.ajkd.2016.03.42127160031]Search in Google Scholar
[64. Miano TA, Lautenbach E, Wilson FP, Guo W, Borovskiy Y, Hennessy. Attributable Risk and Time Course of Colistin-Associated Acute Kidney Injury. Clin J Am Soc Nephrol 2018; 13(4): 542-50.10.2215/CJN.06980717596945729545383]Search in Google Scholar
[65. Ulldemolnis M, Soy D, Liaurado-Serra M, Vaquer S, Castro P, Rodriquez AH, et al. Meropenem Population Pharmacokinetics in Critically Ill Patients with Septic Shock and Continuous Renal Replacement Therapy: Influence of Residual Diuresis on Dose Requirements. Antimicrobial Agenst Chemother 2015; 59(9): 5520-8.10.1128/AAC.00712-15453846826124172]Search in Google Scholar
[66. Eyler RF, Vilay AM, Nader AM, Heung M, Pleva M, Sowinski KM, et al. Pharmacokinetics of Ertapenem in Critically Ill Patients Receiving Continuous Venovenous Hemodialysis or Hemodiafiltration. Antimicrob Agents Chemother 2014; 58(3): 1320-6.10.1128/AAC.02090-12395785024323468]Search in Google Scholar
[67. Roberts JA, Udy AA, Bulitta JB, Stuart J, Jarrett P, Starr T, et al. Doripenem population pharmacokinetics and dosing requirements for critically ill patients receiving continuous venovenous haemodiafiltration. J Antimicrob Chemother 2014; 69(9): 2508-16.10.1093/jac/dku17724879665]Search in Google Scholar
[68. Malone RS, Fish DN, Abraham E, Teitelbaum I. Pharmacokinetics of Levofloxacin and Ciprofloxacin during Continuous Renal Replacement Therapy in Critically Ill Patients. Antimicrob Agents Chemother 2001; 45(10): 2949-54.10.1128/AAC.45.10.2949-2954.20019076211557500]Search in Google Scholar
[69. Wallis S, Mullany D, Lipman J, Rickard C. Pharmacokinetics of ciprofloxacin in ICU patients on continuous veno-venous haemodiafiltration. Int Care Med 2001; 27(4): 665-72.10.1007/s00134010085711398692]Search in Google Scholar
[70. Spooner AM, Deegan C, Darcy DM, Gowing CM, Donnelly MB, Corrigan OI. An evaluation of ciprofloxacin pharmacokinetics in critically ill patients undergoing continuous veno-venous haemodiafiltration. BMC Clinical Pharmacol 2011; 11(1): 11-20.10.1186/1472-6904-11-11316194221816053]Search in Google Scholar